Pituitary Cancer Market to Grow at 9.4% CAGR Through 2033 as Personalized Cancer Care and Emerging Therapies Open New Growth Opportunities

• Two new polls indicate a decline in global and U.S. trust regarding medical advice and the safety of the measles vaccine for children. • Only 19% of 1,143 adult respondents approved of President Donald Trump's handling of measles outbreaks, while 52% expressed disapproval.

• The Society for Maternal-Fetal Medicine released a statement on Tuesday arguing that abortion care is a core component of maternal-fetal practice. • The report notes that 41 states currently ban abortion at some point during pregnancy.

• Researchers are launching a clinical trial to determine if the experimental drug trontinemab can prevent people with high p-tau217 levels from developing dementia. • The study aims to recruit 1,600 participants following previous research showing the drug cleared amyloid plaques, a hallmark of Alzheimer's, in 90% of early-stage patients.

• A new modelling study published in The Lancet suggests European patients may face longer waits for new medicines due to US efforts to lower drug prices. • Researchers analyzed 195 patented medicines that represent $87.9 billion of annual spending in the United States.

• An unvaccinated 40-year-old woman in Jefferson County, Pennsylvania, died from measles complications in 2026. • Pennsylvania has recorded 693 confirmed cases across 38 counties and has refused the CDC Epi-Aid outbreak assistance that six other states requested.

• The World Health Organization expressed cautious optimism regarding the trajectory of the current Ebola outbreak in the Democratic Republic of the Congo. • This event is the second largest Ebola outbreak on record, though overall case counts remain high.

• The Food and Drug Administration is seeking public input on the potential for supervised therapeutic use of psychedelic drugs. • Current federal laws classify hallucinogens like psilocybin and MDMA as Schedule I drugs, meaning they are legally defined as having no accepted medical use.

• Connect Biopharma reported that its asthma trial reduced failures by 66% based on recent patient data. • Lung function improved by 250 mL by Day 7 compared to 120 mL for the placebo group among 160 patients.

• NanoViricides will begin a Phase II clinical trial next week for NV-387, an oral gummy drug designed to treat the Bundibugyo Ebola virus. • The trial responds to an expanding outbreak in the Democratic Republic of Congo where the crude fatality rate has reached 48%.

• NanoViricides will begin a clinical trial next week for the oral drug NV-387 to treat an expanding Ebola outbreak in the Democratic Republic of Congo. • The current outbreak of the Bundibugyo Ebolavirus variant has a 48% crude fatality rate and no approved treatment or vaccine.

• Medical researchers are warning that misinformation and vaccine hesitancy could limit the effectiveness of upcoming personalized cancer vaccines. • These vaccines are designed to prevent cancer from returning by training the immune system to recognize specific proteins on a patient's tumor.